A pharma giant is moving past one patent cliff — but another is already looming
Disappointing data highlights Novartis' challenge to build its next generation of blockbuster medicines, following a series of clinical trial setbacks.
Ringkasan berita
Disappointing data highlights Novartis' challenge to build its next generation of blockbuster medicines, following a series of clinical trial setbacks.
Ikuti berita terkini daripada penerbit yang dipercayai dengan ringkasan ringkas. Buka pautan sumber asal untuk butiran.